Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LK101 Injection in Advanced Solid Tumors (NSCLC)
CTR20261073Phase 2Active
- Sponsor
- Likang Life Sciences
- Start
- Mar 2026
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LK101 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Likang Life Sciences. Primary endpoints: Progression-free survival 1 (PFS1) and Progression-free survival 2 (PFS2). Started Mar 2026; status: active.
02
Drugs
LK101
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261073.